Palisade Bio (PALI) Share-based Compensation (2010 - 2026)
Palisade Bio (PALI) reported Share-based Compensation of $4.3 million for Q1 2026, up 7428.07% year-over-year from $57000.0 in Q1 2025, and up 15.29% quarter-over-quarter from $3.7 million in Q4 2025.
Palisade Bio (PALI) Share-based Compensation (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Share-based Compensation data on file, last reported at $4.3 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $4.3 million, up 7428.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (up 5014.46% YoY), and the FY2025 annual result was $3.9 million, up 2806.67% from the prior year.
- Share-based Compensation climbed to $4.3 million in Q1 2026 per PALI's latest filing, from $3.7 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.3 million in Q1 2026 and troughed at -$440000.0 in Q4 2024.
- A 5-year average of $595058.8 and a median of $125000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation plunged 172.61% in 2024, then soared 7428.07% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $86000.0 in 2022, then jumped by 604.65% to $606000.0 in 2023, then sank by 172.61% to -$440000.0 in 2024, then soared by 945.91% to $3.7 million in 2025, then increased by 15.29% to $4.3 million in 2026.
- Business Quant data shows PALI's Share-based Compensation at $4.3 million in Q1 2026, $3.7 million in Q4 2025, and $85000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - | 4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.29 Mn |
| Mar 31, 2026 | 4.29 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 85,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Dec 31, 2024 | -440,000.00 |
| Dec 31, 2024 | -440,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | 606,000.00 |
| Dec 31, 2023 | 606,000.00 |